ClinicalTrials.gg
RecruitingNCT04664556IPDUpdated Oct 28, 2026

National, Non Interventional Study of Invasive Pneumococcal Disease in Children and Newborns

An observational study in Pneumococcal Infections, Pneumococcal Conjugate Vaccine and Antibiotic Treatment, sponsored by Association Clinique Thérapeutique Infantile du val de Marne. Recruiting at 1 site in France. Open to participants aged 1 Day to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Association Clinique Thérapeutique Infantile du val de Marne · Observational

How we know

From the registry’s dates

  • Started Dec 2010; still recruiting 15 years 11 months later.
Updated Oct 28, 2026Enrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
3,000
Ages
1 Day to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Pneumococcal Infections with a site in France — 2 open to participants now, 2 under way, none of them phase 3. Pneumococcal Infections · France.

Started
2010
the only one that year
Observational
7 of 23
1 open now
Registered
18th of 23
by date
Lead sponsor
1 of 23
Association Clinique Thérapeutique Infantile du val de Marne

Among the 23 studies in Pneumococcal Infections with a site in France, this one is the only one that started in 2010, is one of 7 observational ones, and was the 18th registered.

Pneumococcal Infections

299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

2 of the 23 studies in Pneumococcal Infections with a site in France are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 1 Day to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Pneumococcal Infections with a site in France, or all of them as a file.
02

Study summary

After 7 then 13 valent pneumococcal conjugate vaccine (PCV) implementation in France in children, we will evaluate the impact of this vaccination on invasive pneumococcal disease (IPD). We will describe the clinical characteristics of IPD, pneumococcus serotyping, underlying conditions and vaccination status.

Read the detailed description

For children under 18, hospitalized for IPD, the following data will be analyzed: risk factors, vaccination status, severity signs , treatment during hospitalization, biological analysis, the clinical location of the disease.

03

Conditions studied

  • Pneumococcal Infections
  • Pneumococcal Conjugate Vaccine
  • Antibiotic Treatment
  • Mortality
04

Who can participate

Ages eligible
1 Day to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Children with invasive pneumococcal disease for whom the pneumococcal strain is sent to the National reference Center for Pneumococci for serotyping

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Isolate of Streptococcus pneumoniae from at least one blood culture, or pleural fluid, or joint fluid, or cerebrospinal fluid or other normally sterile body site, or if there is a positive blood polymerase chain reaction (PCR).

Exclusion criteria

Exclusion Criteria:

  • Pneumococcal strain not transmetted to National Reference Center for Pneumococci or to Regional Pneumococci Observatory
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
3,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Severity of invasive pneumococcal disease

    Number of severe cases according to age and pneumococcal serotypes distribution

    Time frame: before hospital discharge

Secondary outcomes

  1. Impact of vaccines

    Number of invasive pneumococcal disease according to vaccine serotypes

    Time frame: before hospital discharge

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Levy C, Estivaux A, Varon E, Bechet S, Ouldali N, Hau I, Cohen R. Pediatric Invasive Pneumococcal Disease Spectrum Before Third-Generation Pneumococcal Conjugate Vaccine Implementation. J Pediatric Infect Dis Soc. 2025 Aug 7;14(7):piaf056. doi: 10.1093/jpids/piaf056. PubMed 40492721 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2010 (actual). Primary completion is estimated for Jan 2030, 228 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2020
First posted
Dec 11, 2020
StartActual
Dec 13, 2010
Primary completionEst.
Jan 1, 2030
CompletionEst.
Jan 1, 2030
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
2500→3000
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Enrollment 2500→3000
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04664556
Lead sponsor
Association Clinique Thérapeutique Infantile du val de Marne
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Dec 11, 2020
Start date
Dec 13, 2010
Primary completion
Jan 1, 2030 (estimated)
Completion
Jan 1, 2030 (estimated)
Last update
Oct 28, 2026

Study contacts

Levy Corinne
Contact
corinne.levy@activ-france.fr
1 48 85 04 04 ext. +33
Bechet Stephane
Contact
stephane.bechet@activ-france.fr
1 48 85 96 68 ext. +33
Levy Corinne
study director · Association Clinique Thérapeutique Infantile du val de Marne
Cohen Robert
principal investigator · Association Clinique Thérapeutique Infantile du val de Marne

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion